BFNH — BioForce Nanosciences Holdings Income Statement
0.000.00%
Last trade - 00:00- $16.92m
- $16.92m
Annual income statement for BioForce Nanosciences Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Total Operating Expenses | 158 | 0.502 | 0.486 | 0.472 | 0.49 |
| Operating Profit | -158 | -0.502 | -0.486 | -0.472 | -0.49 |
| Net Income Before Taxes | -158 | -0.502 | -0.486 | -0.472 | -0.49 |
| Net Income After Taxes | -158 | -0.502 | -0.486 | -0.472 | -0.49 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -158 | -0.502 | -0.486 | -0.472 | -0.49 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -158 | -0.502 | -0.486 | -0.472 | -0.49 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -9.72 | -0.017 | -0.017 | -0.016 | -0.017 |